13F filing recap · Q2 2026
What did Hillman Capital Management buy in Q2 2026?
Reported stock-position changes between this filing and the previous one. US-listed stocks across every Hillman account, including accounts that belong to no fund below.
Stock value
$138.15M
Positions
54
Estimated turnover
15.0%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Hillman Capital Management opened new positions in Dupont De Nemours, Veeva Systems, and Accenture, while exiting General Electric and several SPDR and iShares funds. The firm trimmed CVS Health, Biogen, International Flavors & Fragrances, Carmax, Taiwan Semiconductor, Bristol-Myers Squibb, West Pharmaceutical Services, US Bancorp, Verizon, UnitedHealth, Constellation Brands, Akamai, and Oracle. Notable additions included Conagra Brands, Salesforce, and Medtronic, with a substantial reduction in Price T Rowe Group.